Search Results

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Definium Therapeutics’ closely watched anxiety readout could further validate its single-dose LSD candidate, while Compass Pathways advances a psilocybin program through a rolling FDA filing.

CEO Daniel Haders, PhD, will highlight upcoming catalyst events for the company’s two lead assets: MDL-001, a first-in-class, universal, direct-acting therapeutic for influenza-like-illness (ILI) and chronic hepatitis, targeting the novel RdRp Thumb-1 site, and MDL-4102, a first-in-class therapeutic for various cancers and inflammatory diseases, targeting the epigenetic reader and master regulator of gene transcription, BRD4.

HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.